Normal function · from ai-gene-review (O43175, commit 79fe13b38970) · AI-generated, not KB evidence

PHGDH is human D-3-phosphoglycerate dehydrogenase (3-PGDH; EC 1.1.1.95), an NAD+-dependent oxidoreductase of the D-isomer-specific 2-hydroxyacid dehydrogenase family that assembles as a homotetramer and acts in the cytosol. It catalyzes the first and rate-limiting step of the phosphorylated pathway of de novo L-serine biosynthesis, oxidizing the glycolytic intermediate 3-phospho-D-glycerate to 3-phosphonooxypyruvate (3-phosphohydroxypyruvate) with reduction of NAD+ to NADH. Serine produced by this pathway supplies one-carbon units, nucleotides, glycine, phospholipids and redox cofactors. Human PHGDH additionally displays secondary NAD+-dependent 2-hydroxyacid dehydrogenase side-activities, most notably reduction of 2-oxoglutarate to the oncometabolite D-2-hydroxyglutarate, and in vitro malate dehydrogenase activity. Biallelic loss-of-function variants cause the serine-deficiency disorders phosphoglycerate dehydrogenase deficiency (congenital microcephaly, psychomotor retardation, seizures) and the more severe Neu-Laxova syndrome 1, while PHGDH amplification/overexpression drives serine biosynthesis in a subset of cancers. Two enzyme-independent moonlighting activities have additionally been reported in Alzheimer's-disease models: a nuclear, chromatin-associated transcriptional-regulator role acting through a predicted DNA-binding helix-helix-turn-helix subdomain, and, separately, an RNA-binding activity that binds the EIF2AK1 3'UTR and promotes BACE1 translation. Both are stated to be independent of catalysis, the second also independent of the first; both come from a single laboratory and neither has been independently replicated.

NAD+-dependent oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first and rate-limiting step of de novo L-serine biosynthesis.
Binds the NAD+ cofactor required for hydride transfer during the phosphoglycerate dehydrogenase reaction, via a Rossmann-fold NAD(H)-binding domain.
molecular function: NAD binding
Catalyzes step 1 of the phosphorylated pathway of de novo L-serine biosynthesis in the cytosol, supplying serine for one-carbon metabolism, nucleotide, glycine and lipid synthesis.
molecular function: phosphoglycerate dehydrogenase activity · locations: cytosol
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
3-Phosphoglycerate Dehydrogenase Deficiency causative germline
mechanism: PHGDH Enzyme Deficiency
subtype: Adult; Infantile; Juvenile; Neu-Laxova
Ewing Sarcoma no genetic record
mechanism: ATF4-Serine-Glycine Metabolic Reprogramming
INPP5K-Related Congenital Muscular Dystrophy no genetic record
mechanism: PHGDH Dysregulation
ClinGen gene–disease validity · snapshot 2026-10-03 · matched to entries by MONDO

An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.

ClinGen diseaseMOIClassificationdismech entry
neurometabolic disorder due to serine deficiency MONDO:0018162 AR Definitive
2020-06-29
no dismech entry

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.